Pharmacolog forms an international consortium for Eurostars application

Pharmacolog has, together with a consortium consisting of the University of Lille, University Hospital in Geneva and Munkplast AB, submitted a Eurostar application for a project to develop solutions for adaptive medication with intravenous drugs.

Pharmacolog has, in collaboration with GRITA, the University of Lille, France, the University Hospital in Geneva and Munkplast AB in Uppsala submitted a Eurostar application accepted for further assessment within the Eureka / Eurostars organization.

The project; Intravenous Dose Rate Adjustment (IDRA) refers to the development of methods and systems for adaptive treatment with intravenous drugs and is scheduled to last over three years with a total budget of approximately 15 million SEK. A granted Eurostars application implies a financial contribution of up to 50% of the total project budget.

Eurostars is a cooperation program between EUREKA and the European Commission with joint funding from 36 participating countries, partner countries and the EU through the Horizon 2020 program. Eurostar’s budget over the period 2014-2020 is a total of EUR 1.14 billion. Eurostars supports international innovative cooperation projects led by small and medium-sized development companies.

Research Director Hans Dahlin comments, “I am extremely pleased that we have managed to gather two world-leading medical institutions and a Swedish company that are experts in the production of plastic products with the aid of robot automation. An approval of the project will significantly accelerate our efforts to develop solutions that enable real-time adjustment of the drug dose during ongoing treatment with intravenous drugs. The project is in line with our vision as well as the EU-focused medical research projects in the area of Personlized Medicine

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...

Study in Lille completed

The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.

The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially result...

DrugLog® will be evaluated by a hospital chain in New York

Pharmacolog and one of New York’s most reputable hospital chains have signed an agreement that DrugLog® should be evaluated at two of the organization’s hospitals for use in a Drug Diversion program. The hospital chain pays for the evaluation scheduled to start in December and is expected to be completed in the first quarter of 2018.

Theft of narcotic intravenous drugs in healthcare is an growing problem. In the US, the authorities have initiated various preventive actions as the abuse of opiates reaches alarming levels. Since DrugLog can identify such drugs and also see if they have been manipulated in any way, DrugLog is a useful tool to prevent this development. The interest in usi...

Nyemissionen registrerad

Pharmacolog i Uppsala AB (publ) har genomfört en nyemission med företrädesrätt för befintliga aktieägare med teckningstid 27 september – 13 oktober 2017 efter beslut av styrelsen den 28 augusti med stöd av bemyndigande från Bolagets årsstämma den 3 maj 2017. Emissionen, som övertecknades, tillförde Bolaget 19,6 MSEK före emissionskostnader.

Emissionen har registrerats av Bolagsverket den 1 november 2017. I samband med att emissionen har registrerats av Bolagsverket kommer betalda tecknade aktier (BTA) att avregistreras och ersättas av nya aktier. Sista dag för handel med BTA på Aktietorget är den 6 november 2017.

Genom nyemissionen har aktiekapitalet i Pharmacolog ökat med 1 178 799,90 SEK...